Two additions to executive team and vp of sales and marketing in US
European contract manufacturer NextPharma Technologies has made two key additions to its executive team. Andrew Kelley has been appointed chief operating officer, while Pierre Delavaud has become executive vice president of sales and marketing.
In addition, Matthew Wilder has been appointed as vice president US sales and marketing to help drive the company’s business in the country.
Kelley has more than 27 years of experience in the pharmaceutical industry, most recently at Patheon.
Delavaud joins the NextPharma team from SkyePharma, having previously spent 14 years at Catalent, where he held various senior positions.
Wilder has more than 10 years of sales and marketing experience in the US pharmaceutical industry and comes to the company from Sanofi Pharmaceuticals, where he held a number of senior positions.
Franck Latrille, chief executive of NextPharma, said: ‘This is an exciting time for the company, and we are confident that with the injection of their expertise to the team, we can continue to improve our business offerings.’